Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defining actionable mutations for oncology therapeutic development.

Nature reviews. Cancer - 26 Apr 2016

Carr T Hedley, McEwen Robert, Dougherty Brian, Johnson Justin H, Dry Jonathan R, Lai Zhongwu, Ghazoui Zara, Laing Naomi M, Hodgson Darren R, Cruzalegui Francisco, Hollingsworth Simon J, Barrett J Carl

Abstract excerpt

Genomic profiling of tumours in patients in clinical trials enables rapid testing of multiple hypotheses to confirm which genomic events determine likely responder groups for targeted agents. A key challenge of this new capability is defining which specific genomic events should be classified as 'actionable' (that is, potentially responsive to a targeted therapy), especially when looking for early indications of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pyrazoles

Share to Pyrimidines

Share to Pyrimidinones

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 27112209
DOI: 10.1038/nrc.2016.35

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defining actionable mutations for oncology therapeutic development.PMID 27112209Read ↗

Data resources for the identification and interpretation of actionable mutations by clinicians.Semantic proximity Read ↗

Targeting mutations in cancer.Semantic proximity Read ↗

Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.Semantic proximity Read ↗

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.Semantic proximity Read ↗

Molecularly profiled trials: toward a framework of actions for the "nil actionables".Semantic proximity Read ↗

Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Semantic proximity Read ↗

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Semantic proximity Read ↗

Get the basics of genetic mutations in oncology.Semantic proximity Read ↗

A framework for genomic biomarker actionability and its use in clinical decision makingSemantic proximity Read ↗

Biomarker-driven patient selection for early clinical trialsSemantic proximity Read ↗

Actionable Alterations for Molecular Targeted Therapy in Esophageal Cancer: An AACR Project GENIE ReviewSemantic proximity Read ↗

Identification of putative actionable alterations in clinically relevant genes in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.